ReviewCureus2025
Insights Into Mammary and Extramammary Paget's Disease: Diagnosis, Management, and Recent Advances.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- S1 guideline sweat gland carcinoma.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Guideline
- Treatment of extramammary Paget's disease with sirolimus: A case series.JAAD case reports · 2026Article
- Imaging features of an extramammary Paget's disease of the penis: A case report and literature review.Radiology case reports · 2026Article
- Rare Localization of Extramammary Paget's Disease in the Axilla: A Case Report and Literature Review.Journal of clinical medicine · 2025Article
- Perianal Paget's Disease: A Report of a Rare Case.Cureus · 2025Article
- Secondary Perianal Paget's Disease Originating From Adenocarcinoma of the Anorectal Junction: A Case Report.Clinical, cosmetic and investigational dermatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mammary Paget's disease (MPD) and extramammary Paget's disease (EMPD) are rare cutaneous disorders associated with adenocarcinoma, each presenting unique clinical challenges. MPD typically indicates an underlying breast cancer, manifesting as eczematous changes in the nipple-areolar complex. In contrast, EMPD appears as erythematous, scaly plaques in apocrine-gland-rich areas such as the vulva, perianal region, or axilla, with inconsistent links to internal malignancies. These conditions often resemble benign skin diseases, complicating timely diagnosis. Diagnosis involves clinical evaluation, imaging, and histopathological confirmation of Paget cells. Pathogenesis may stem from in situ malignant transformation or migration of cancer cells from distant sites, influenced by molecular pathways like HER2 and PI3K-AKT-mTOR. Treatment varies: MPD often requires mastectomy and systemic therapies, while EMPD is managed with surgical excision (e.g., Mohs surgery), adjusted to disease extent. The prognosis hinges on stage, molecular features, and associated tumors, particularly impacting MPD survival. Recent advances in precision medicine and immunotherapy, especially for EMPD, offer promising directions. This review highlights the distinct features, diagnostic hurdles, treatment strategies, and the essential role of a multidisciplinary approach in improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.